Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study
Objectives. Colorectal cancer is responsible for more than two million cases diagnosed annually. Despite early diagnosis through screening programs and adequate treatment, 25% of cases are diagnosed with metastatic disease while up to 50% of patients diagnosed early progress to metastatic disease. M...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-04-01
|
| Series: | Journal of Mind and Medical Sciences |
| Subjects: | |
| Online Access: | https://scholar.valpo.edu/cgi/viewcontent.cgi?article=1477&context=jmms |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256021048524800 |
|---|---|
| author | Adrian Paul Suceveanu Dragos Serban Andreea Daniela Caloian Georgeta Camelia Cozaru Anca Chisoi Anca Antonela Nicolau Ioan Sergiu Micu Andra Iulia Suceveanu |
| author_facet | Adrian Paul Suceveanu Dragos Serban Andreea Daniela Caloian Georgeta Camelia Cozaru Anca Chisoi Anca Antonela Nicolau Ioan Sergiu Micu Andra Iulia Suceveanu |
| author_sort | Adrian Paul Suceveanu |
| collection | DOAJ |
| description | Objectives. Colorectal cancer is responsible for more than two million cases diagnosed annually. Despite early diagnosis through screening programs and adequate treatment, 25% of cases are diagnosed with metastatic disease while up to 50% of patients diagnosed early progress to metastatic disease. Materials and Methods. The study of 40 patients aims to identify the role of placental growth factor and heparin-binding growth factor as prognostic tools for current treatments involving resistance to bevacizumab in metastatic colorectal cancer. Results. Our results suggested that overall survival was influenced by serum fibroblast growth factor 1 levels. A cut-off value of 260.71 pg/ml was considered predictive of a disease-free survival/DFS of 6 months to 1 year, while a cut-off value of 117.51 pg/ml was considered predictive of a better DFS. Regarding placental growth factor involvement, a serum level of 13.75 pg/ml as a first determination and 11.48 pg/ml after 8 months of chemotherapy and anti-vascular endothelial growth factor therapy were considered cut-off values for 1- to 3-year overall survival/OS, while 6.45 pg/ml and 8.12 pg/ml levels were considered cut-off levels for 3- to 5-year OS. Conclusions. The results of the current study detected cutoff levels that may better predict treatment resistance in advanced-stage colorectal cancer and poor OS and DFS rates. Serum levels of placental growth factor and fibroblast growth factor 1 at diagnosis become important prognostic factors predicting resistance to bevacizumab in metastatic colorectal cancer. |
| format | Article |
| id | doaj-art-3da95b16a1b44d69ab6c5bc44cdcd3d2 |
| institution | OA Journals |
| issn | 2392-7674 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Mind and Medical Sciences |
| spelling | doaj-art-3da95b16a1b44d69ab6c5bc44cdcd3d22025-08-20T01:56:45ZengMDPI AGJournal of Mind and Medical Sciences2392-76742024-04-0111117518210.22543/2392-7674.1477Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET studyAdrian Paul Suceveanu0Dragos Serban1Andreea Daniela Caloian2Georgeta Camelia Cozaru3Anca Chisoi4Anca Antonela Nicolau5Ioan Sergiu Micu6Andra Iulia Suceveanu7Ovidius University of Constanta, Faculty of Medicine, Department of Gastroenterology, Constanta, RomaniaCarol Davila University of Medicine and Pharmacy, Emergency University Hospital Bucharest, 4th Department of General Surgery, Bucharest, RomaniaOvidius University of Constanta, Faculty of Medicine, Department of Oncology, St. Apostol Andrew Emergency Clinical Hospital, Constanta, RomaniaOvidius University of Constanta, Faculty of Medicine, Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology, Constanta, RomaniaOvidius University of Constanta, Faculty of Medicine, Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology, Constanta, RomaniaOvidius University of Constanta, Faculty of Medicine, Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology, Constanta, RomaniaOvidius University of Constanta, Faculty of Medicine, Doctoral School of Medicine, Constanta, RomaniaOvidius University of Constanta, Faculty of Medicine, Department of Gastroenterology, Constanta, RomaniaObjectives. Colorectal cancer is responsible for more than two million cases diagnosed annually. Despite early diagnosis through screening programs and adequate treatment, 25% of cases are diagnosed with metastatic disease while up to 50% of patients diagnosed early progress to metastatic disease. Materials and Methods. The study of 40 patients aims to identify the role of placental growth factor and heparin-binding growth factor as prognostic tools for current treatments involving resistance to bevacizumab in metastatic colorectal cancer. Results. Our results suggested that overall survival was influenced by serum fibroblast growth factor 1 levels. A cut-off value of 260.71 pg/ml was considered predictive of a disease-free survival/DFS of 6 months to 1 year, while a cut-off value of 117.51 pg/ml was considered predictive of a better DFS. Regarding placental growth factor involvement, a serum level of 13.75 pg/ml as a first determination and 11.48 pg/ml after 8 months of chemotherapy and anti-vascular endothelial growth factor therapy were considered cut-off values for 1- to 3-year overall survival/OS, while 6.45 pg/ml and 8.12 pg/ml levels were considered cut-off levels for 3- to 5-year OS. Conclusions. The results of the current study detected cutoff levels that may better predict treatment resistance in advanced-stage colorectal cancer and poor OS and DFS rates. Serum levels of placental growth factor and fibroblast growth factor 1 at diagnosis become important prognostic factors predicting resistance to bevacizumab in metastatic colorectal cancer.https://scholar.valpo.edu/cgi/viewcontent.cgi?article=1477&context=jmmsmetastatic colorectal cancerbevacizumabplacental growth factorheparin-binding growth factorfibroblast growth factor 1vascular endothelial growth factor |
| spellingShingle | Adrian Paul Suceveanu Dragos Serban Andreea Daniela Caloian Georgeta Camelia Cozaru Anca Chisoi Anca Antonela Nicolau Ioan Sergiu Micu Andra Iulia Suceveanu Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study Journal of Mind and Medical Sciences metastatic colorectal cancer bevacizumab placental growth factor heparin-binding growth factor fibroblast growth factor 1 vascular endothelial growth factor |
| title | Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study |
| title_full | Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study |
| title_fullStr | Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study |
| title_full_unstemmed | Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study |
| title_short | Correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer; the AVAMET study |
| title_sort | correlation between molecular prognostic factors and bevacizumab therapeutic resistance in patients with metastatic colorectal cancer the avamet study |
| topic | metastatic colorectal cancer bevacizumab placental growth factor heparin-binding growth factor fibroblast growth factor 1 vascular endothelial growth factor |
| url | https://scholar.valpo.edu/cgi/viewcontent.cgi?article=1477&context=jmms |
| work_keys_str_mv | AT adrianpaulsuceveanu correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy AT dragosserban correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy AT andreeadanielacaloian correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy AT georgetacameliacozaru correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy AT ancachisoi correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy AT ancaantonelanicolau correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy AT ioansergiumicu correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy AT andraiuliasuceveanu correlationbetweenmolecularprognosticfactorsandbevacizumabtherapeuticresistanceinpatientswithmetastaticcolorectalcancertheavametstudy |